Next Generation Modeling of Glioblastoma Progression: Diffusing Through Time and Brain
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Department of Clinical Neurosciences Student
Department of Clinical Neurosciences Student
Abstract
Description
In the momentous tide of advanced medical physics and neuroimaging capabilities that have transformed neurological and neurosurgical clinical practice and research, it is crucial to mobilize this effort against incurable pathologies, such as glioblastoma (GBM). GBM is a malignant WHO Grade 4 brain tumor that inevitably recurs post-operatively and is fatal. With diffusion tensor imaging, we can now detect tumor cells’ occult infiltration of white matter tracts in the brain, with insight into the trajectory that GBM progression will take. However, an extra step is needed to predict that trajectory, which is a separate endeavor from only visualizing it. Mathematical modeling of glioma cell “diffusion” within the brain has been broadly reported, but with limited practical application. To improve predictive modeling for refining treatment, we review diffusion from a physics and mathematical framework, beginning with contributions from Joseph Fourier and proceeding to the modern day. We then focus on drawing a distinctive connection to advanced medical physics and neuroimaging capabilities and how they can be operationalized to better model GBM progression.
FMC is funded by the Amma Kyei-Mensah Medical Scholarship and the Stamps Scholarship through Queens’ College, University of Cambridge. YW is supported by Cancer Research UK Clinical Research Training Fellowship and by the CRUK Cambridge Centre. The PRaM-GBM study was funded from Cancer Research UK (C9216/A19732). This work was supported by the NIHR HealthTech Research Centre in Brain Injury and the NIHR Cambridge Biomedical Research Centre (NIHR203312). This publication presents independent research funded by the National Institute for Health and Care Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
FMC is funded by the Amma Kyei-Mensah Medical Scholarship and the Stamps Scholarship through Queens’ College, University of Cambridge. YW is supported by Cancer Research UK Clinical Research Training Fellowship and by the CRUK Cambridge Centre. The PRaM-GBM study was funded from Cancer Research UK (C9216/A19732). This work was supported by the NIHR HealthTech Research Centre in Brain Injury and the NIHR Cambridge Biomedical Research Centre (NIHR203312). This publication presents independent research funded by the National Institute for Health and Care Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.